426 related articles for article (PubMed ID: 27544060)
1. Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer.
Lin JJ; Kennedy E; Sequist LV; Brastianos PK; Goodwin KE; Stevens S; Wanat AC; Stober LL; Digumarthy SR; Engelman JA; Shaw AT; Gainor JF
J Thorac Oncol; 2016 Nov; 11(11):2027-2032. PubMed ID: 27544060
[TBL] [Abstract][Full Text] [Related]
2. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
[TBL] [Abstract][Full Text] [Related]
3. Alectinib activity in chemotherapy-refractory metastatic RET-rearranged non-small cell lung carcinomas: A case series.
Ribeiro MFSA; Alessi JVM; Oliveira LJC; Gongora ABL; Sacardo KP; Zucchetti BM; Shimada AK; de Galiza Barbosa F; Feher O; Katz A
Lung Cancer; 2020 Jan; 139():9-12. PubMed ID: 31698333
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II study of alectinib in lung cancer with RET fusion gene: study protocol.
Takeuchi S; Murayama T; Yoshimura K; Kawakami T; Takahara S; Imai Y; Kuribayashi Y; Nagase K; Goto K; Nishio M; Hasegawa Y; Satouchi M; Kiura K; Seto T; Yano S
J Med Invest; 2017; 64(3.4):317-320. PubMed ID: 28955006
[TBL] [Abstract][Full Text] [Related]
5. Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer.
McKeage K
Drugs; 2015 Jan; 75(1):75-82. PubMed ID: 25428710
[TBL] [Abstract][Full Text] [Related]
6. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.
Gainor JF; Sherman CA; Willoughby K; Logan J; Kennedy E; Brastianos PK; Chi AS; Shaw AT
J Thorac Oncol; 2015 Feb; 10(2):232-6. PubMed ID: 25526238
[TBL] [Abstract][Full Text] [Related]
7. Rapid and dramatic response to alectinib in an anaplastic lymphoma kinase rearranged non-small-cell lung cancer patient who is critically ill.
Yoshida T; Hida T; Yatabe Y
Anticancer Drugs; 2016 Jul; 27(6):573-5. PubMed ID: 26938871
[TBL] [Abstract][Full Text] [Related]
8. Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against
Fujimura T; Furugaki K; Harada N; Yoshimura Y
Cancer Biol Ther; 2020 Sep; 21(9):863-870. PubMed ID: 32835580
[TBL] [Abstract][Full Text] [Related]
9. Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial.
Felip E; Smit EF; Molina-Vila MA; Dafni U; Massuti B; Berghmans T; de Marinis F; Passiglia F; Dingemans AC; Cobo M; Viteri S; Britschgi C; Cuffe S; Provencio M; Merkelbach-Bruse S; Andriakopoulou C; Kammler R; Ruepp B; Roschitzki-Voser H; Peters S; Wolf J; Stahel R;
Lung Cancer; 2022 Oct; 172():94-99. PubMed ID: 36030612
[TBL] [Abstract][Full Text] [Related]
10. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.
Kodama T; Tsukaguchi T; Satoh Y; Yoshida M; Watanabe Y; Kondoh O; Sakamoto H
Mol Cancer Ther; 2014 Dec; 13(12):2910-8. PubMed ID: 25349307
[TBL] [Abstract][Full Text] [Related]
11. Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer.
Santarpia M; Altavilla G; Rosell R
Expert Rev Respir Med; 2015 Jun; 9(3):255-68. PubMed ID: 25652176
[TBL] [Abstract][Full Text] [Related]
12. Clinical Efficacy of Alectinib in Patients with
Oya Y; Yoshida T; Kuroda H; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
Anticancer Res; 2017 Nov; 37(11):6477-6480. PubMed ID: 29061835
[TBL] [Abstract][Full Text] [Related]
13. Alectinib for the treatment of ALK-positive stage IV non-small cell lung cancer.
Wong KM; Noonan S; O'Bryant C; Jimeno A
Drugs Today (Barc); 2015 Mar; 51(3):161-70. PubMed ID: 25876560
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.
Yoshimura Y; Kurasawa M; Yorozu K; Puig O; Bordogna W; Harada N
Cancer Chemother Pharmacol; 2016 Mar; 77(3):623-8. PubMed ID: 26849637
[TBL] [Abstract][Full Text] [Related]
15. Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.
Zhu V; Ou SH
Expert Opin Drug Saf; 2017 Apr; 16(4):509-514. PubMed ID: 28276856
[TBL] [Abstract][Full Text] [Related]
16. Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC.
Lin JJ; Zhu VW; Schoenfeld AJ; Yeap BY; Saxena A; Ferris LA; Dagogo-Jack I; Farago AF; Taber A; Traynor A; Menon S; Gainor JF; Lennerz JK; Plodkowski AJ; Digumarthy SR; Ou SI; Shaw AT; Riely GJ
J Thorac Oncol; 2018 Oct; 13(10):1530-1538. PubMed ID: 29935304
[TBL] [Abstract][Full Text] [Related]
17. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
Ou SH; Greenbowe J; Khan ZU; Azada MC; Ross JS; Stevens PJ; Ali SM; Miller VA; Gitlitz B
Lung Cancer; 2015 May; 88(2):231-4. PubMed ID: 25736571
[TBL] [Abstract][Full Text] [Related]
18. Alectinib for ALK-positive non-small-cell lung cancer.
Rossi A
Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1005-13. PubMed ID: 27232673
[TBL] [Abstract][Full Text] [Related]
19. Alectinib: A Review in Advanced, ALK-Positive NSCLC.
Paik J; Dhillon S
Drugs; 2018 Aug; 78(12):1247-1257. PubMed ID: 30030733
[TBL] [Abstract][Full Text] [Related]
20. Alectinib for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401).
Iwama E; Goto Y; Murakami H; Harada T; Tsumura S; Sakashita H; Mori Y; Nakagaki N; Fujita Y; Seike M; Bessho A; Ono M; Okazaki A; Akamatsu H; Morinaga R; Ushijima S; Shimose T; Tokunaga S; Hamada A; Yamamoto N; Nakanishi Y; Sugio K; Okamoto I
J Thorac Oncol; 2017 Jul; 12(7):1161-1166. PubMed ID: 28238961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
